Navigation Links
UIC in NIH-funded islet transplantation study for type 1 diabetes
Date:7/8/2008

The University of Illinois at Chicago is one of 11 centers in the United States, Canada, Sweden and Norway to participate in the Clinical Islet Transplant Consortium funded by the National Institutes of Health.

Consortium researchers have begun clinical studies to test new approaches to islet transplantation that may lead to improved outcomes and fewer side effects for adults with difficult-to-control type 1 diabetes.

Patients with type 1 diabetes depend on multiple daily insulin injections or an insulin pump because their own immune system destroys the insulin-producing cells of the pancreas. They often develop life-threatening complications, including damage to the heart and blood vessels, eyes, nerves and kidneys.

Islet transplantation offers the most promise for achieving insulin independence, glucose control and freedom from hypoglycemic attacks for type 1 diabetics, says Dr. Jos Oberholzer, principal investigator and director of cell and pancreas transplantation at UIC.

"This research will help us find the most effective combination of anti-rejection drugs to maximize islet engraftment while reducing toxic side effects," said Oberholzer.

"The ultimate goal is to refine islet transplantation and generate an unlimited supply of islets so that many more people would benefit from this treatment," he said.

Islet transplantation involves isolating islets from a donor pancreas and infusing the cells into the main blood vessel in the patient's liver. If the transplant is successful, the islets lodge in the small blood vessels of the liver and begin producing insulin. Patients must take drugs to suppress their immune system and prevent rejection of the islets. In some cases, patients require more than one infusion of donor islets to produce enough insulin.

At UIC, patients will be enrolled in three protocols to evaluate a combination of different medications to protect the newly transplanted islet cells.


'/>"/>

Contact: Sherri McGinnis Gonzalez
smcginn@uic.edu
312-996-8277
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. NIH-funded Vanderbilt Research Seeks Ways to Avoid Information Overload in Health Care Choices Among Seniors
2. The new source of islet cells
3. Living donors may be best source of insulin-producing islets for diabetes treatment
4. Studies test new approaches to islet transplantation
5. Islet Cell Transplants Aid Type 1 Diabetics
6. Promising advances in islet cell transplants for diabetes
7. A rare association: Non-islet cell tumor hypoglycemia
8. American Society of Transplantations Past President Testifies Before Congress at Forum on Organ Donation
9. Patients over age 60 do well after liver transplantation
10. No racial differences seen in outcomes after liver transplantation
11. Predicting survival after liver transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. ... office is now offering a variety of comprehensive procedures for facial enhancement. The ... facial volume restoration, lip enhancement and nasal reshaping. , As a result, ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Ongoing news of ... Life Care Association™ (ALCA) to conduct a survey that takes a closer look at ... today illustrates the prevalence and causes of TBI among the aging population, and identifies ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors (UBA), ... latest addition to its growing list of Partner Firms. S.S. Nesbitt is ... Orlando to Huntsville and in between. , Harnessing the experience and insights of ...
(Date:2/10/2016)... ... 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company ... and full year ended December 31, 2015 on Monday, February 29, 2016 after the ... investment community following the release at 4:30 PM ET. Investors interested in participating by ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... time Emmy award winner and inspirational speaker Jan Fox will serve as keynote ... Speaking Boldly will provide participants with tools to more effectively communicate with their ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Feb. 9, 2016 On Tuesday, ... (FDA) met with its Arthritis Advisory Committee ... of Johnson & Johnson,s Remicade and most ... in the U.S. The Biologics Prescribers Collaborative ... - Alliance for Patient Access, American Association ...
(Date:2/10/2016)... 2016 Demonstrates changes in ... receptor selectivity   1 receptor ... entered clinical development as a new treatment for ...   --> 1 receptor agonist, ... clinical development as a new treatment for cognitive ...
(Date:2/9/2016)... Corporation (NASDAQ: PODD ) (Insulet or the Company), the ... OmniPod ® Insulin Management System, today announced ... Insulet,s Board of Directors. With his appointment, the Board is ... --> --> Mr. Lemoine ... a deep knowledge of accounting, financial reporting and internal controls ...
Breaking Medicine Technology: